Table 3.

Adverse events on oral micronized progesterone (300 mg at bedtime) or Placebo in perimenopausal women participating in a randomized double blind 12-Week trial for hot flushes and night sweats (n = 189).

	Adverse event	Progesterone N = 93	Control N = 96
1	Musculoskeletal, arthritis, connective tissue issues	6 (6.5%)	1 (1.1%)
2	Nausea, GI tract problems	8 (8.3%)	1 (1.1%)
3	Dizziness^	1 (1.0%)	1 (1.1%)
4	Edema, **atrial fibrillation, increased blood pressure, and headache	5 (5.2%)	3 (3.2%)
5	Worsening VMS	0	*1 (1.1%)
6	Post-traumatic stress	0	1 (1.1%)
7	Probable depression	1 (1.0%)	0
8	Facial acne	1 (1.0%)	0

*Discontinuation related to an adverse event on placebo.

**Family Physician-mandated discontinuation from progesterone experimental therapy.

^The only experience potentially related to progesterone therapy in blinded adjudication.